Treating Relapsed/Refractory MM: Sequencing of Therapies
Release Date: October 26, 2020
Expiration Date: October 26, 2021
This activity is for clinicians who treat patients with multiple myeloma (hematologists, medical oncologists, oncology nurses and nurse practitioners, oncology pharmacists).
After completing this activity, participants should be better able to:
- Evaluate best available evidence regarding the treatment of patients with multiple myeloma
- Assess the implications of emerging clinical trial data regarding multiple myeloma treatment approaches
- Develop strategies to address complicated multiple myeloma cases
The University of Nebraska Medical Center, Center for Continuing Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
The University of Nebraska Medical Center, Center for Continuing Education designates this enduring material for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education through the joint providership of the University of Nebraska Medical Center, Center for Continuing Education and Bio Ascend.
Method of Participation
There are no fees for participating and receiving credit for this activity. During the accredited period, participants must 1) read the learning objectives and faculty disclosures; 2) study the educational activity; 3) complete the pre- and post-activity assessments and evaluation.
Participants who complete the educational activity, pre- and post-activity assessments, and evaluation will receive a certificate of credit.
As a provider accredited by ACCME, the University of Nebraska Medical Center, Center for Continuing Education must ensure balance, objectivity, independence, and scientific rigor in its educational activities. Presenters are encouraged to provide a balanced view of therapeutic options by utilizing either generic names or the trade names of several to ensure impartiality. All presenters, planners, and others in a position to control continuing medical education content participating in a University of Nebraska Medical Center, Center for Continuing Education activity are required to disclose relationships with commercial interests.
A commercial interest is any entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients. Disclosure of these commitments and/or relationships is included in activity materials so that participants in the activity may formulate their own judgments in interpreting its content and evaluating its recommendations.
This activity may include presentations in which presenters may discuss off-label and/or investigational use of pharmaceuticals or instruments not yet FDA-approved. Participants should note that the use of products outside currently FDA-approved labeling should be considered experimental and are advised to consult current prescribing information for FDA-approved indications. All materials are included with the permission of the authors. The opinions expressed are those of the authors and are not to be construed as those of the University of Nebraska Medical Center, Center for Continuing Education or Bio Ascend. The information presented in this activity is not meant to serve as a guideline for patient management; primary references, relevant practice guidelines, and full prescribing information should be consulted.
All faculty and planning committee members have no conflicts to disclose with the exception of the following:
Sagar Lonial, MD, FACP
Chief Medical Officer
Professor and Chair, Department of Hematology and Medical Oncology
Anne and Bernard Gray Family Chair in Cancer
Winship Cancer Institute of Emory University
Consulting Fees: Amgen Inc., Bristol-Myers Squibb Company, Celgene Corporation, GlaxoSmithKline LLC, Janssen Oncology, Karyopharm Therapeutics, Merck & Co., Novartis
Paul Richardson, MD
R.J. Corman Professor of Medicine
Harvard Medical School
Dana-Farber Cancer Institute
Advisory Committees: Celgene Corporation/BMS, Janssen Oncology, Karyopharm Therapeutics, Oncopeptides, Sanofi Genzyme, Takeda Pharmaceutical Company
Research Support: Bristol Myers Squibb, Celgene Corporation, Oncopeptides, Takeda Pharmaceutical Company
This activity is supported by independent educational grants from Bristol Myers Squibb, GlaxoSmithKline LLC, and Oncopeptides
Select the Continue button below to begin. You may return later if you are unable to complete the activity at this time.